Previously, we demonstrated that treatment of postconfluent quiescent rat aortic smooth muscle cells (SMCs) with platelet-derived growth factor (PDGF)-BB dramatically reduced smooth muscle (SM) a-actin synthesis. In the present studies, we focused on the expression of two other SM-specific proteins, SM myosin heavy chain (SM-MHC) and SM a-tropomyosin (SM-aTM), to determine whether the actions of PDGF-BB were specific to SM a-actin or represented a global ability of PDGF-BB to inhibit expression of cell-specific proteins characteristic of differentiated SMCs. SM-MHC and SM-aTM expression were assessed by one-or 
A ccelerated smooth muscle cell (SMC) growth is known to play an integral role in atherosclerotic lesion formation1-2 and is a characteristic feature in arteries of hypertensive patients and animals. 3 The proliferating SMCs within atherosclerotic lesions are phenotypically altered with respect to normal medial SMCs,4,5 and it has been suggested that the phenotypic state of a vascular SMC may have an important influence on the growth properties of the cell.6 Therefore, it is of fundamental importance to understand the factors that regulate SMC growth and phenotypic state in order to understand vascular pathobiology. Our recent work has focused on the ability of platelet-derived growth factor (PDGF) and 10% fetal bovine serum (FBS) to induce changes in the expression of the smooth muscle (SM)-specific contractile protein SM a-actin as a marker for change in SM phenotype. Interestingly, although 10% FBS was as mitogenic as PDGF, FBS did not alter the expression of SM a-actin mRNA, whereas PDGF suppressed the expression of SM a-actin mRNA by 70-80%. 7 Additional studies demonstrated that continuous exposure of SMCs to PDGF maintained an 80% inhibition of SM a-actin synthesis but did not maintain cells in a proliferative state, as measured by thymidine labeling indexes.8 differentiated SMC is contraction, the contractile proteins represent logical candidates to assess the differentiated state of SMCs. Whereas SMC differentiation has been described using a two-state model in which cells exist in either a "contractile" or "synthetic" state, 6 it is important that SMC differentiation be considered as a continuum of SMC phenotypes ranging from that of a committed, but as yet undifferentiated, SMC in the embryo to the mature fully differentiated SMC in a blood vessel. As such, quantitative and qualitative measurements of SM-specific gene products can be used to assess the relative position of cells on the continuum as well as the effects of positive and negative regulators of SM phenotype.
SMCs express a number of isoforms of contractile proteins that are either selective or unique to SM, including SM a-actin, SM The principal aim of the present study was to determine whether PDGF affects SM a-actin selectively or whether it also suppresses expression of other SMspecific proteins such as SM-MHC and SM-aTM. Additional studies deal with the relation between growth and cytodifferentiation in cultured SMCs by comparing the effects of serum-versus PDGF-BB-induced growth on expression of these SM-specific contractile proteins. Finally, we investigated whether PDGF-BB or PDGF-AA exert differential effects on the expression of SM-specific contractile proteins.
Materials and Methods Cell Culture
Rat thoracic aortic SMCs were isolated and cultured as described previously.13 Cells were grown for 5 days after initial confluence in Dulbecco's modified Eagle's medium (GIBCO, Grand Island, N.Y.) and Ham's F12 (GIBCO) containing 10% FBS (Hyclone Laboratories Inc., Logan, Utah), 200 ,g/ml L-glutamine, 100 units/ml penicillin (GIBCO), and 100 ,ug/ml streptomycin (GIBCO). Cells were switched to a defined serum-free medium containing equal parts of Dulbecco's modified Eagle's medium and Ham's F12 supplemented with 1 ,uM insulin (Sigma Chemical Co., St. Louis, Mo.), 5 gg/ml transferrin (Sigma), 200 ug/ml L-glutamine, 0.2 mM ascorbate (Sigma), 6.25 ng/ml sodium selenite tomycin for 5 days to induce quiescence and to promote expression of SM-specific contractile proteins. Phenotypic modulation of SMCs is a sine qua non of cell culture and undoubtedly begins when cells are placed in vitro. However, the culture system used in these studies has been previously described and is widely used for the culture of vascular SMCs, which continue to express SM-specific genes including SM-MHC, SM myosin light chain, SM-aTM, SM a-actin, and a variety of other markers appropriate for vascular SMCs and exhibit agonist-induced phosphorylation of myosin light chain and agonist-induced shape changes consistent with contraction (References 9 and 14-16 and authors' unpublished observations). Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO2-95% air with media changes every 2-3 days.
RNA Preparation
For the RNA studies, cells were treated for 24 hours with 0. 
RNA Blots and Hybridization
For gel electrophoresis, 10 ,ug total RNA was denatured by heating for 10 minutes at 65°C in a solution of 4.4 M formaldehyde and 5% formamide and resolved on a 1% agarose gel containing 2.2 M formaldehyde. The RNA was transferred to a nylon membrane (Micron Separations Inc., Westboro, Mass.) by Northern blotting. The resulting blot was heated to 80°C under vacuum for 2 hours and subsequently exposed to an ultraviolet transilluminator (254 nm, 500 ,uW/cm2) for 1 minute, air-dried, and stored until used.
Rat SM-MHC mRNA was identified using a 373-bp cDNA probe corresponding to SM2-type MHC (provided by Drs. P. Babij and M. Periasamy, University of Vermont, Burlington).10 This cDNA probe recognizes both the SM1 and SM2 isoforms of SM-MHC but not nonmuscle MHC. SM-aTM was identified using a 128-bp cDNA probe specific to exon 2 of the rat SM-aTM gene.12 The exon 2-specific probe was isolated by the polymerase chain reaction from a cDNA containing exons 1, 2, and 4 of SM-aTM (provided by Drs. M. Taubman and B. Nadal-Ginard, Harvard Medical School, Boston). Exon 2 was subcloned into pGEM 3zf(-), and the linearized plasmid containing the insert was used in random priming reactions. All probes were labeled with [a-_3P]dCTP using Prime-a-Gene reagents (Promega Corp., Madison, Wis.). All blots were hybridized and washed using the method of Church and Gilbert.23 The blots were dried and exposed to Kodak X-Omat AR or K film at -70°C in the presence of an intensifying screen. The optical densities of hybridization signals on x-ray films were measured using a model FB934 densitometer (Fisher Biotech).
Mitogenic Studies
Relative rates of DNA synthesis were assessed by determination of [3H]thymidine incorporation into trichloroacetic acid-precipitable material as previously described.13 Cells were pulsed for 6 hours (18-24 hours after agonist treatment) with ['H]thymidine (2 , uCi/ml) and then washed once with cold phosphate-buffered saline. This was followed by one 10-minute wash with 10% (wtlvol) cold trichloroacetic acid at 4°C and one 10-minute wash with 10% trichloroacetic acid at 22°C. Cells were then dissolved in 1N NaOH, placed in scintillation fluid, and counted. Quadruplicate dishes were analyzed per sample.
Statistical Analysis
Multiple means were first analyzed by analysis of variance (ANOVA). When ANOVA led to rejection of the null hypothesis, means were compared using Dunnett's tests, with p<0.05 considered to be statistically significant. Results *Significantly greater than PDGF-BB (20 ng/ml) treatment by Dunnett's test (p<00.5).
SM-MHC and SM-aTM
tSignificantly less than PDGF-BB (20 ng/ml)+1% FBS treatment group by Student's t test (p<O.05).
PDGF-BB and FBS had additive effects in stimulating [3H]thymidine incorporation into DNA (Table 2) . However, addition of FBS did not prevent PDGF-BBinduced decreases in either SM-MHC or SM-aTM mRNA expression ( Figure 6 ). Therefore, these data indicate that the failure of FBS to reduce SM-aTM was not due to a factor present in FBS that inhibits the effects of PDGF-BB on SMC differentiation.
Discussion
The results reported in this article demonstrate that PDGF-BB markedly decreased the expression of two SM-specific contractile proteins, SM-aTM and SM-MHC. These results, in addition to previously reported effects of PDGF-BB on SM a-actin,726 are consistent with the hypothesis that PDGF-BB elicits a global suppression of expression of cell-specific proteins characteristic of differentiated SMCs. The ability of PDGF-BB to enhance proliferation and suppress differentiation in SMCs is similar to the effect of PDGF-BB and another growth factor, basic fibroblast growth factor, in skeletal muscle. Treatment with these growth factors stimulates myoblast proliferation and concomitantly decreases cell fusion and expression of skeletal muscle myosin.24,27 Although these results are consistent with the dogma of an inverse relation between cell growth and cytodifferentiation, the nature of this relation in SM remains controversial. We7, 16 and others28 have previously demonstrated that expression of SM a-actin, but not SM a-actin mRNA,7 is downregulated during logarithmic growth of SMCs in serum-containing medium. Additionally, the ability of heparin to upregulate SM a-actin expression appears to be correlated with its antiproliferative activity.29 Consistent with results of earlier studies suggesting that SM-MHC expression may be growth-regulated,9'25 we observed decreased SM-MHC expression with both serum-and PDGF-induced mitogenesis. However, the expression of SM-aTM, as well as previous studies demonstrating that serum-induced growth was not associated with decreased expression of SM a-actin mRNA,7,30 indicates that growth, per se, is not associated with coordinate downregulation of the entire differentiation program. These findings indicate a fundamental difference between SMCs and skeletal myoblasts, in that SMCs, unlike skeletal myoblasts, are capable of sustained expression of at least some differentiated proteins during cellular proliferation. Furthermore, results of these studies suggest that the dedifferentiation of SMCs, as occurs in atherosclerotic lesions of humans,4,5 as well as myointimal lesions in experimental animal models of atherosclerosis,4,31 may be the consequence of the action of specific differentiation suppressor molecules such as PDGF-BB, which are known to be present within intimal lesions,32-34 rather than a direct consequence of accelerated SMC proliferation per se. Indeed, at least in cultured SMCs, PDGF of platelet origin appears to be able to maintain suppression of SM a-actin synthesis after thymidine labeling indexes have returned to basal levels,8 further supporting a possible role for PDGF-BB as a differentiation suppressor molecule for SMCs.
The failure of FBS to suppress SM a-actin and SM-aTM expression does not appear to be due to a serum factor that partially inhibits PDGF-BB-associated repression, since the PDGF-induced inhibition of expression of SM a-actin protein26 or SM-MHC and SM-aTM mRNAs was not blocked by high concentrations of serum. Interestingly, no other purified growth factor, including insulin (a necessary component of serum-free medium), transforming growth factor-fl, basic fibroblast growth factor, or epidermal growth factor, appears to inhibit SM a-actin expression in our SMCs, suggesting a unique role for PDGF-BB in the control of dedifferentiation of SMCs (Reference 26 and authors' unpublished observations). It was observed, however, that 10% FBS elicited a modest decrease in SM-MHC mRNA expression, suggesting a role for serum factors in SMC differentiation. These results are in contrast to those reported recently by Babij et al,35 who reported that withdrawal of 10% FBS for 2 days did not elicit an increase in SM-MHC mRNA in confluent SMCs. Although the mechanisms that underlie the differences in action among these mitogens are unknown, these studies clearly indicate that the extent of repression of SM-specific protein expression is not a simple function of the extent of cellular proliferation.
To date, PDGF-BB has proven to be capable of suppressing protein and mRNA expression of three SM-specific proteins. The correlation between the decrease in SM-aTM and SM-MHC mRNA levels and protein synthesis would suggest a transcriptional control of expression. However, results of our previous studies indicate that PDGF-BB-induced decreases in SM a-actin expression are not mediated transcriptionally but rather via selective decreases in the stability of the SM a-actin mRNA.36 It remains to be determined whether PDGF-BB-induced changes in SM-aTM and SM-MHC expression are under transcriptional control.
PDGF-induced downregulation of SM-aTM and SM-MHC in the present studies appeared to be mediated via the PDGF ,f-receptor, since the cultured SMCs used in these studies lacked detectable PDGF a-receptors, according to ['"I]PDGF-AA binding studies, and failed to undergo a mitogenic response to PDGF-AA (authors' unpublished observations). These results are consistent with our previous observations showing that repression of SM a-actin by PDGF was not dependent on the PDGF-A chain. It is estimated that at least 15,000-30,000 active a-subunits per cell are required for PDGF-AA-induced mitogenesis.37'38 Since the SMCs used in these studies lacked this number of receptors and failed to respond mitogenically to PDGF-AA, our results cannot be interpreted as evidence for qualitatively different effects of PDGF a-versus fl-receptors on SMC differentiation, since it is possible that, under conditions in which SMCs express sufficient a-receptor subunits, PDGF-AA might elicit similar effects.
In summary, results of these and previous studies show that PDGF-BB is an extremely potent and efficacious agent in inducing coordinate downregulation of expression of multiple SM-specific proteins. In contrast, serum failed to downregulate SM a-actin and SM-aTM and only modestly decreased SM-MHC expression.
These results suggest that PDGF-BB may play an important role in the regulation of the differentiated state of SMCs and that this role may be distinct from its role as a mitogen.
